LEADER 03472nam  22005535  450 
001 9910300446603321
005 20200704054445.0
010   $a3-319-61421-5
024 7 $a10.1007/978-3-319-61421-2
035   $a(CKB)4100000006995958
035   $a(MiAaPQ)EBC5529939
035   $a(DE-He213)978-3-319-61421-2
035   $a(PPN)230539122
035   $a(EXLCZ)994100000006995958
100   $a20180929d2018      u|         0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aBone Marrow Failure /$fedited by Gary M. Kupfer, Gregory H. Reaman, Franklin O. Smith
205   $a1st ed. 2018.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2018.
215   $a1 online resource (217 pages)
225 1 $aPediatric Oncology,$x1613-5318
311   $a3-319-61420-7 
327   $a1. The Cellular and Molecular Mechanisms of Hematopoiesis -- 2. Acquired Aplastic Anemia -- 3. Pediatric Myelodysplastic Syndromes -- 4. Fanconi Anemia: A Pathway of Hematopoeisis and Cancer Predisposition -- 5. Ribosomopathies Through a Diamond Lens -- 6. Dyskeratosis Congenita and the Telomere Biology Disorders -- 7. Diamond Blackfan Anemia -- 8. Shwachman-Diamond Syndrome -- 9. Hematopoietic Cell Transplantation for the Treatment of Patients with Bone Marrow Failure Syndromes -- 10. Inherited Neutropenias and Their Insights into Cellular and Developmental Biology -- 11. Inherited Thrombocytopenias.
330   $aThis book presents the latest scientific knowledge on inherited and acquired bone marrow failure syndromes, describing the advances in understanding of genetics and pathophysiology that have been achieved as a result of high-throughput DNA sequencing, RNA expression studies, and modern biochemistry techniques. The full range of relevant conditions is covered, including acquired aplastic anemia, Fanconi anemia, ribosomopathies, telomeropathies, dyskeratosis congenita, Shwachman-Diamond syndrome, Diamond-Blackfan anemia, and congenital neutropenias and thrombocytopenias. In addition, it is explained how the study of these rare diseases has uncovered important new science and elucidated the pathophysiology of more common hematological and oncological diseases. A treatment-specific chapter describes options ranging from the conventional to the cutting edge. Bone Marrow Failure will be of value for both trainee and practicing hematologists and oncologists.
410  0$aPediatric Oncology,$x1613-5318
606   $aOncology
606   $aPediatrics
606   $aHematology
606   $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160
606   $aPediatrics$3https://scigraph.springernature.com/ontologies/product-market-codes/H49006
606   $aHematology$3https://scigraph.springernature.com/ontologies/product-market-codes/H3307X
615  0$aOncology.
615  0$aPediatrics.
615  0$aHematology.
615 14$aOncology.
615 24$aPediatrics.
615 24$aHematology.
676   $a616.41
702   $aKupfer$b Gary M$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aReaman$b Gregory H$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aSmith$b Franklin O$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910300446603321
996   $aBone Marrow Failure$91742958
997   $aUNINA